Emageon extends backlog, strikes credit deal
Current contracts signed by PACS and IT developer Emageon have extended the company's backlog of orders to a figure in excess of $100 million. Emageon attributes much of its success to partnering with large integrated delivery networks (IDNs), including
Current contracts signed by PACS and IT developer Emageon have extended the company's backlog of orders to a figure in excess of $100 million. Emageon attributes much of its success to partnering with large integrated delivery networks (IDNs), including Kaiser Permanente, Sisters of Mercy, Sutter Health, Allina Hospitals and Clinics, and Aurora Health Care. To date, more than 70 acute care hospitals and imaging facilities have implemented Emageon products. The company, which expects to complete 30 additional hospital implementations this year, currently has a customer base of more than 250 sites. Supporting future growth is a new agreement with IBM that will allow Emageon customers to obtain IBM Global Financing, providing a single-source agreement for financing Emageon products and services.
FDA Grants Fast Track Designation to Emerging Agent for Brain PET Imaging
June 11th 2025Currently being evaluated in a phase 2b clinical trial, the 18F-RAD101 PET imaging agent garnered the FDA’s fast track designation for distinguishing between recurrent disease and treatment impact for brain metastases derived from solid tumors.
New PSMA PET Prep Product Now Available in the U.S.
June 11th 2025Offering an extended shelf life, the FDA-approved Gozellix, a preparation kit for gallium-68 (68Ga) gozetotide injection, is indicated for use in PSMA PET imaging of prostate cancer patients with suspected recurrence or metastasis.
